PT - JOURNAL ARTICLE AU - Zheng, Yi AU - Sun, Lijun AU - Xu, Mi AU - Pan, Jian AU - Zhang, Yuntao AU - Fang, Xueling AU - Fang, Qiang AU - Cai, Hongliu TI - Clinical characteristics of 34 COVID-19 patients admitted to ICU in Hangzhou, China AID - 10.1101/2020.04.12.20062604 DP - 2020 Jan 01 TA - medRxiv PG - 2020.04.12.20062604 4099 - http://medrxiv.org/content/early/2020/04/15/2020.04.12.20062604.short 4100 - http://medrxiv.org/content/early/2020/04/15/2020.04.12.20062604.full AB - Introduction The purpose of the study was to summarize the clinical and laboratory characteristics of the coronavirus disease 2019 patients admitted to intensive care unit.Methods We tracked the data until March 5, 2020. The cases in our cohort were divided into cases only received noninvasive ventilation (NIV) and cases required invasive mechanical ventilation (IMV). The characteristics between the two groups were compared.Results 34 cases were included in the study. The complications rate (including, acute liver injury, acute cardiac injury and acute kidney injury) were higher in IMV cases. Lymphocytopenia and neutrophilia occurred in most cases in both groups on the admission day, however, lymphocyte levels dropped progressively and more severe lymphopenia occurred in IMV group. Increased amounts of plasma IL-6 and IL-10 were found in both groups on the admission day, the progressive decrease of which occurred in NIV cases rather than IMV cases, and the levels were higher in IMV cases during hospitalization.Conclusions Lymphocytopenia, neutrophilia, and increase of IL-6 and IL-10 occurred in SARS-CoV-2 infected patients in ICU, however, the dynamics of those were significantly different in IMV cases and NIV cases during hospitalization.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work is funded by the Project for Emergency of Key R & D Plan from Zhejiang Science and Technology Agency (2020C03123).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data will be made available to others on reasonable requests to the corresponding author.COVID-19coronavirus disease 2019ICUIntensive care unitNIVnoninvasive ventilationIMVinvasive mechanical ventilationIQRinterquartile rangeCOPDchronic obstructive pulmonary diseaseHFNCHigh-flow nasal cannulaECMOextracorporeal membrane oxygenationLDHlactate dehydrogenaseSARSsevere acute respiratory syndromeMERSMiddle East respiratory syndromeP/FPaO2/FiO2ARDSacute respiratory distress syndromeAKIacute kidney injuryALTalanine aminotransferaseULNupper limit of the normal rangeASTaspartate aminotransferaseIPPVInvasive positive pressure ventilationCRRTcontinuous renal replacement therapyBUNblood urea nitrogenPICSpersistent inflammation-immunosuppression and catabolism syndrome